Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
Bottles of Corona beer speed past a worker in the bottling line of Mexico City's Modelo brewery, May 19, 2004. REUTERS/Andrew Winning He may be in for worse than a surprise: a nasty skin reaction that one doctor is calling "Mexican beer dermatitis." A substance in lime juice, if left on the skin in the sun, can cause the skin to become discolored, as if by poison ivy or a jellyfish sting and the marks can last for months, reports Scott Flugman in the Archives of Dermatology. Mexican beers, particularly Corona, are typically served with a lime slice wedged in the top of the bottle. The drinker shoves the lime into the bottle and holds his or her thumb over the bottle's mouth while turning the bottle over to mix in the juice. But if the drinker is not careful, the beer's carbonation can spray lime juice and beer all over his or her skin "especially in a patient who is shirtless by a beach or pool," wrote Flugman, a dermatologist in New York. The resulting reaction is due to a substance called psoralen, used to make the skin more sensitive to a wavelength of ultraviolet light, UV-A, used to treat certain skin conditions. Lemons contain psoralens too, but not as strong. "It's just a cosmetic issue," Flugman told Reuters Health, though he said the discoloration most frequently in people like bartenders who work outdoors with limes may take an emotional toll. "People are worried that it's something serious. You might have some brown spots you're been looking at for a few months," he said. Olive-skinned Caucasians may be especially susceptible. No ties have been shown between the reaction and skin cancer, said Flugman, who added that he sees two or three cases a year. They are often mystified why a dermatologist is asking them if they've recently drunk Mexican beer. His advice? "If you do this and you spritz the beer or the lime, just wash it off. Don't leave it on there and sit out in the sun," he said. Or, if you are disinclined to get up for a while, "throw a towel over it."

Ex Output:
Hold the lime with Corona, may cause skin reaction.

Ex Input:
The story makes clear the "big unknown" remains the price and "how much people are willing to spend to cut a day or so off of a bout of flu." The story reports that Genentech, the drug's manufacturer, said it's too early to comment on the drug's U.S. price. The story also notes that in Japan, where the drug was invented, it "sells for the equivalent of about $43.50." The story uses terms like "a little more than a day" and "nearly a day" and "substantially" to describe the drug's reduction in flu symptoms, fever, and coughing and sneezing, respectively. It does not explain, as the news release does, that: "Similar efficacy results were seen between baloxavir marboxil and [Tamiflu] in relation to duration of symptoms and fever reduction." In other words, on the symptom front, both drugs were the same. According to the news release, a difference was seen in the length of time the virus was shed from the body (presumably through coughing and sneezing): 24 hours for baloxavir marboxil verses 72 hours for Tamiflu. The news release also states that there was also a difference seen in the level of virus in the nose and throat, but it provides no precise numbers. It is not known whether this benefit translates into less infection transmission, and the story should have made that clear. The news release issued by Genentech about the FDA's decision to grant priority review describes baloxavir marboxil's most common side effects: diarrhea, bronchitis, nausea and sinusitis. The news release also states that overall incidence of adverse events seen in patients taking baloxavir marboxil were lower than those seen in both the placebo group and the group taking Tamiflu. The STAT News story does not mention any potential harms. This evidence comes from the randomized phase III Capstone-1 study the FDA will review, which included 1,436 people in the US and Japan. It excluded people older than 64. The news story does not note this exclusion, nor does it state a key problem with this study: It has never been published in a peer-reviewed journal (instead, a study abstract was released as part of ID Week 2017). This means the full data analysis has never been seen by anyone other than the researchers. We explained why this is important in February 2018, when we discussed news coverage of the drug's approval in Japan. The 2017-2018 flu season was the worst the US had experienced in nearly a decade. The flu impacted the entire country, and was responsible for 172 pediatric deaths. The news article did not use these or any other flu-related statistics to increase fear about the flu and, in turn, the need for this medication. The article includes two sources: Mark Eisner, Genentech's VP of product development for immunology, infectious diseases and ophthalmology and Richard Webby, head of the World Health Organization's influenza collaborating center at St. Jude Children's Research Hospital in Memphis. Eisner's affiliation with Genentech, the drug's manufacturer, is clearly noted. Webby does not appear to have any conflicts of interest. The article would have been stronger if it had included a third source who commented on whatif anythingis known about whether reducing the duration of symptoms leads to reduced levels of transmission that result in fewer people contracting the flu and fewer deaths. The story explains that the only other drug approved to treat the flu is Tamiflu, which is not widely used. The writer explains that both drugs need to be taken within 48 hours of symptom onset and thatbaloxavir marboxil is a single one-time dose, while Tamiflu must be taken twice daily for five days. It is clear from the story that the FDA is expected to decide by the end of the year whether to approve this new flu medication. The story explains that it's been more than 20 years since a new class of flu drug has been developed and marketed. (It is available in Japan.) The catalyst for the story was a news release issued by Genentech about the FDA granting priority review of baloxavir marboxil, but the story does not use direct quotes from the news release.

Ex Output:
A flu drug shown to reduce the duration of symptoms could upend treatment in U.S.

Ex Input:
Homebred beef cattle are seen at a local cattle market in Hongseong, about 170 km (106 miles) south of Seoul July 29, 2008. A rare genetic mutation may underlie some cases of mad cow disease in cattle and its discovery may help shed light on where the epidemic started, U.S. researchers reported on Friday. REUTERS/Lee Jae-Won The mutation, in an Alabama cow that tested positive in 2006 for bovine spongiform encephalopathy, or BSE, is identical to one that causes a related brain-wasting disease in humans. This suggests BSE may sometimes arise spontaneously in cattle. Jurgen Richt of Kansas State University said cattle producers must never let down their guard against BSE because cattle anywhere, at any time, can develop the disease. The finding may support a 2005 theory that the BSE epidemic in cattle could be traced to feed contaminated with cattle remains from India, the researchers report in the Public Library of Science journal PLoS Pathogens. BSE or mad cow disease swept through British dairy herds in the 1980s, forcing the destruction of millions of animals. No one ever found where it came from but most experts thought at the time it came from cattle feed that contained the remains of sheep infected with a similar disease called scrapie. Cattle were never known to develop BSE before the epidemic, but some experts have argued they may have. This report lends credence to that idea. BSE, scrapie and a human version called Creutzfeldt-Jakob disease, or CJD, are brain-destroying illnesses called transmissible spongiform encephalopathies. In some cases, animals or people that eat brain and nervous system material from victims of these diseases can develop them, too. They are passed along by misfolded infectious protein fragments called prions. A very rare disease called variant CJD has been found in people who ate infected beef products. Fatal and incurable, it has affected just 167 people so far. Most countries now ban the use of meat and other parts from mammals in food for cattle. They also ban the use of potentially infectious tissues such as brain and spinal cord in human food. "There are tendencies around the world, now that the feed-borne epidemic has gone down, to relax these rules and regulations," Richt said in a telephone interview. "So if we have these genetic cases popping up here and there and we don't have our mitigations in place, we will have another epidemic somewhere." He suggested breeding the gene out of cattle. "We can clean the world cattle herd of that mutation," Richt said. CJD is also known to pop up spontaneously in the human population. A genetic mutation causes the disease in one in a million people globally. Richt and colleagues tested the brain of the Alabama cow and found a mutation identical to the prion gene mutation that causes some cases of CJD. It is probably rare in cattle, found in fewer than one in 2,000, they said in the report, published here But the animal passed along its mutation to its heifer, which suggests it is inherited.

Ex Output:
Gene mutation underlies some mad cow disease: study.